Drug Trial Radar · NCT00392925
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
Last checked: Nov 20, 2026Latest source record: Apr 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
177
Actual
Start
Oct 2006
Primary completion
Sep 2007
Study completion Sep 2007
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 26, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously.
Conditions
- Overweight
- Obesity
Interventions
pramlintide acetate 360 mcgDrug
subcutaneous injection, twice a day, 360mcg
metreleptinDrug
subcutaneous injection, twice a day, 5mg
placebo-pramlintide 600 uLDrug
twice a day
placebo-metreleptin 1 mLDrug
twice a day
Pramlintide acetate 180 mcgDrug
subcutaneous injection twice a day, 180 mcg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Absolute Change From Baseline to Week 16 in Body Weight - Evaluable PopulationTime frame: Baseline to Week 16
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Research Site
DeLand, Florida
Research Site
Chicago, Illinois
Research Site
Indianapolis, Indiana
Research Site
Overland Park, Kansas
Research Site
Baton Rouge, Louisiana
Research Site
Detroit, Michigan
Research Site
Edina, Minnesota
Research Site
Butte, Montana
Research Site
Cincinnati, Ohio
Research Site
Portland, Oregon
Research Site
Salt Lake City, Utah
Research Site
Olympia, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.